Impel Neuropharma

News

FDA turns down Satsuma’s nasal migraine treatment

Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101.

News

Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

News

Agios shares slide as it abandons sickle cell candidate

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks